ERK Inhibitor ASN007 Effectively Overcomes Acquired Resistance to EGFR Inhibitor in Non-small Cell Lung Cancer

Bo Mi Ku(Samsung Medical Center), Myung‐Ju Ahn(Samsung Medical Center)
Research Square
February 23, 2021
10.21203/rs.3.rs-249758/v1
Cited by 0

Related Papers

MDSC subtypes and CD39 expression on CD8 <sup>+</sup> T cells predict the efficacy of anti‐PD‐1 immunotherapy in patients with advanced NSCLC
|European Journal of Immunology|2020|90
Caffeine Inhibits Cell Proliferation and Regulates PKA/GSK3β Pathways in U87MG Human Glioma Cells
|Molecules and Cells|2011|76
Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer
|Investigational New Drugs|2019|50
CpG oligodeoxynucleotides induce IL-8 expression in CD34+ cells via mitogen-activated protein kinase-dependent and NF-κB-independent pathways
|International Immunology|2005|40
Mutational status of <i>TP53</i> defines the efficacy of Wee1 inhibitor AZD1775 in <i>KRAS</i>-mutant non-small cell lung cancer
|Oncotarget|2017|40